The mechanism of Gei Herba against type 2 diabetes mellitus: an integration of gut microbiota and network pharmacology analysis
Open Access
- 28 January 2026
- journal article
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 54 (1) , 119-131
Abstract
The present study aimed to dissect the underlying mechanism of the Gei Herba (LBZ) in the treatment of type 2 diabetes mellitus (T2DM) based on the gut microbiota and network pharmacology strategies. Thirty-one compounds from LBZ were screened and 187 corresponding targets were identified through the database and literature screening. Multiple disease-associated gene and target databases were used to screen and obtain 726 T2DM-related targets. The gutMGene v1.0 database was used for searching metabolites and targets of gut microbiota. 168 overlapping targets of LBZ, T2DM and the gut microbiota were matched and used to build a protein-protein interaction network and perform enrichment analysis. By bioinformatics analysis of microbiota-pathway-target-compound network, the PI3K-Akt signalling pathway was identified, and potential gut probiotics, such as Eubacterium limosum and Lactobacillus paracasei, were found. Subsequently, the core active compounds in LBZ bind to the core targets were verified by molecular docking, all of which exhibited good binding affinity. Finally, four compounds, eleutheroside A, gallic acid, kaempferol, and protocatechuic acid, were found to conform to Lipinski's rule and be non-toxic, showing great potential in the treatment of T2DM. These findings suggest the potential mechanism of LBZ in the treatment of T2DM and the core compounds, such as eleutheroside A may be the promising candidates for T2DM treatment.Keywords
Funding Information
- Scientific Research Projects of Higher Education Institutions in Hebei Province (QN2025158)
This publication has 30 references indexed in Scilit:
- Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 DiabetesDiabetes Therapy, 2025
- Efficacy of microbiome-targeted interventions in obesity management- A comprehensive systematic reviewDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2025
- Unveiling the molecular mechanisms and clinical implications of maslinic acid in diabetes mellitus: Insights from network pharmacologyAspects of Molecular Medicine, 2024
- Association between major depressive disorder or depressive symptoms and the risk of vascular complications among patients with type 2 diabetes, and the mediating role of metabolic biomarkers: an analysis of the UK Biobank cohorteClinicalMedicine, 2024
- Integrating transcriptomics, metabolomics, and network pharmacology to investigate multi-target effects of sporoderm-broken spores of Ganoderma lucidum on improving HFD-induced diabetic nephropathy ratsJournal of Pharmaceutical Analysis, 2024
- The total tannins of Geum japonicum Thunb. var. chinense extracted by green and natural deep eutectic solvent: Extraction optimization, component identification and hypoglycemic activityIndustrial Crops and Products, 2024
- Downregulation of VEGFA accelerates AGEs-mediated nucleus pulposus degeneration through inhibiting protective mitophagy in high glucose environmentsInternational Journal of Biological Macromolecules, 2024
- Eight Zhes Decoction ameliorates the lipid dysfunction of nonalcoholic fatty liver disease using integrated lipidomics, network pharmacology and pharmacokineticsJournal of Pharmaceutical Analysis, 2023
- Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective reviewMolecular and Cellular Biochemistry, 2022
- Protocatechuic acid improves hepatic insulin resistance and restores vascular oxidative status in type-2 diabetic ratsEnvironmental Toxicology and Pharmacology, 2021